Josh Mali, MD, of The Eyes Associates, joins HCPLive to review the key news and developments coming out of the American Society of Retina Specialists 2021 Scientific Meeting.
0:12 Welcome
1:03 Introducing Josh Mali, MD
1:43 New port delivery system & faricimab talking points
3:54 The clinical impact of ranibizumab PDS
6:54 The patient’s perception of PDS
9:27 Improving long-term anti-VEGF trials
11:17 Retina gene therapies to watch out for
13:40 The expanding gene therapy reach
16:34 Promising candidates for dry AMD
19:25 Final thoughts
21:48 Outro
The American Society of Retina Specialists (ASRS) 2021 Scientific Meeting, generally a summer-based event, moved its schedule to early October in light of the COVID-19 pandemic.
The move, fittingly, lined up the annual retina care meeting to within a few weeks of other hugely pertinent discussions and developments in ophthalmic care; to name a couple, the American Academy of Ophthalmology (AAO) meeting will occur later this month, and the US Food and Drug Administration’s (FDA’s) PDUFA date for ranibizumab via port delivery system (PDS) is due in weeks.
The convergence of landmark regulatory decisions and developing data for promising therapies in retina care made ASRS 2021 a perfectly-timed meeting for discussion of where ophthalmology is—and where it is headed.
In a special episode of DocTalk, Joshua Mali, MD, of The Eye Associates, joins to discuss some of the key conversations and data presentations highlighting ASRS 2021.
Among Mali’s most anticipated discussions are that of ranbizumab PDS, continued observations of faricimab for age-related macular degeneration (AMD), gene therapy progression and expansion, and the continued pursuit of the first regulated agent for patients with dry AMD.
